Thursday, June 19, 2025 6/19/2025

Infection-blocking antibody targets for malaria

Award Number: R01AI117234
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2016
PERIOD OF PERFORMANCE END DATE: 09/30/2018

Group Awards By:

View Award Description

Infection-blocking antibody targets for malaria - DESCRIPTION (provided by applicant): A vaccine capable of targeting and neutralizing sporozoites, the infectious stage of the malaria parasites injected by mosquito bite, remains a promising target for preventing malaria infection and transmission. Analysis of malaria vaccine trials has shown that antibodies can neutralize the sporozoite and prevent infection of the liver. However, the most clinically advanced pre-erythrocytic vaccine candidate based on the circumsporozoite protein (CSP) confers only partial protection, indicating that it is necessary to add new antigen targets to increase vaccine efficacy. The overall goal of this proposal is to evaluate novel Plasmodium falciparum pre-erythrocytic antigen candidates that can elicit protective immunity from infection. Building on our recent unprecedented characterization of the P. falciparum sporozoite surface/secreted proteome, we have identified a number of promising surface/secreted antigens that warrant interrogation as new vaccine candidates. Based on this evidence, we will develop 15 P. falciparum sporozoite surface/secreted antigens in a state-of-the-art recombinant protein expression platform and evaluate whether they can elicit protective immunity against mosquito bite sporozoite infection. We will employ an innovative combination of transgenic Plasmodium parasite technology, B cell cloning techniques and humanized rodent models to develop a comprehensive pre-erythrocytic antigen development pipeline for analysis of antibody-mediated protection. In addition, we will evaluate the mechanisms of vaccine-elicited protective humoral immunity against the parasite and deepen our understanding of B cell-mediated protective immunity. Our experimental systems to study the human pathogen P. falciparum in a fully humanized humoral immunogenicity mouse model and a liver- humanized mouse challenge model will ensure our results provide the closest possible approximation of vaccination-elicited responses in humans. The outcomes of our aims will provide an evidence-based selection of novel vaccine candidates and will accelerate their pathway toward human clinical trials using the P. falciparum challenge model. If successful, novel non-CSP vaccine immunogens identified can be considered for inclusion into next generation multi-antigen subunit malaria vaccines.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = -$134 )
2022	2020	SEATTLE CHILDREN'S HOSPITAL	4800 SAND POINT WAY NE	SEATTLE	WA	98105	KING	USA	Allergy and Infectious Diseases Research	000	6	3/28/2022	NON-COMPETING CONTINUATION	-$60
2022	2018	SEATTLE BIOMEDICAL RESEARCH INSTITUTE	307 WESTLAKE AVE N STE 500	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	002	3	6/29/2022	NON-COMPETING CONTINUATION	-$74
2022	2017	SEATTLE BIOMEDICAL RESEARCH INSTITUTE	307 WESTLAKE AVE N STE 500	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	001	2	6/29/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = -$134

Issue Date FY: 2020 ( Subtotal = $826,064 )
2020	2020	SEATTLE CHILDREN'S HOSPITAL	4800 SAND POINT WAY NE	SEATTLE	WA	98105	KING	USA	Allergy and Infectious Diseases Research	000	6	3/12/2020	NON-COMPETING CONTINUATION	$826,064
														Subtotal = $826,064

Issue Date FY: 2019 ( Subtotal = $813,375 )
2019	2019	SEATTLE CHILDREN'S HOSPITAL	4800 SAND POINT WAY NE	SEATTLE	WA	98105	KING	USA	Allergy and Infectious Diseases Research	002	5	3/11/2019	NON-COMPETING CONTINUATION	$845,571
2019	2018	SEATTLE CHILDREN'S HOSPITAL	4800 SAND POINT WAY NE	SEATTLE	WA	98105	KING	USA	Allergy and Infectious Diseases Research	000	4	12/21/2018	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$393,856
2019	2018	SEATTLE CHILDREN'S HOSPITAL	4800 SAND POINT WAY NE	SEATTLE	WA	98105	KING	USA	Allergy and Infectious Diseases Research	004	4	4/30/2019	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$104,161
2019	2018	SEATTLE BIOMEDICAL RESEARCH INSTITUTE	307 WESTLAKE AVE N STE 500	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	001	3	12/24/2018	NON-COMPETING CONTINUATION	-$426,052
2019	2018	SEATTLE BIOMEDICAL RESEARCH INSTITUTE	307 WESTLAKE AVE N STE 500	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	003	3	4/30/2019	NON-COMPETING CONTINUATION	-$104,161
														Subtotal = $813,375

Issue Date FY: 2018 ( Subtotal = $882,051 )
2018	2018	SEATTLE BIOMEDICAL RESEARCH INSTITUTE	307 WESTLAKE AVE N STE 500	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	3	3/9/2018	NON-COMPETING CONTINUATION	$882,051
														Subtotal = $882,051

Issue Date FY: 2017 ( Subtotal = $850,549 )
2017	2017	SEATTLE BIOMEDICAL RESEARCH INSTITUTE	307 WESTLAKE AVE N STE 500	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	2	3/20/2017	NON-COMPETING CONTINUATION	$850,549
														Subtotal = $850,549

Issue Date FY: 2016 ( Subtotal = $850,549 )
2016	2016	SEATTLE BIOMEDICAL RESEARCH INSTITUTE	307 WESTLAKE AVE N, STE 500	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	1	3/22/2016	NEW	$850,549
														Subtotal = $850,549

Grand Total All Awards = $4,222,454

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Infection-blocking antibody targets for malaria

Award Number: R01AI117234

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2016

PERIOD OF PERFORMANCE END DATE: 09/30/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer